Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: Results from a nationwide patient survey
Introduction
In the recent years, enormous diagnostic and therapeutic progress in the field of spondyloarthritides (SpA) has been made. New classification criteria for SpA have been developed and diagnostic procedures such as MRI have been thoroughly studied in different SpA populations [1], [2], [3]. In addition, treatment guidelines for ankylosing spondylitis and other SpAs such as psoriatic arthritis have been introduced and just recently treat-to-target recommendations for the management of SpA were published [4], [5], [6]. Against this background, only little is known about how patients with the SAPHO syndrome, a rare and heterogeneous disease counted among the SpAs, profit from these advances. Other than in the typical SpA population, no data from randomized controlled trials is available, and it is unlikely to have this data in the future due to the infrequency of the syndrome.
The acronym SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) has been proposed by Chamot et al. [7] in order to summarise a variety of previously described syndromes characterised by the common occurrence of osteoarticular and cutaneous symptoms [8], [9], [10]. Despite discussions since its first mention, the term is now established and widely accepted in the literature and 2 sets of diagnostic criteria have been introduced by Kahn and Benhamou [11], [12]. Both focus on the common occurrence of osteoarticular symptoms and either acne or pustulosis palmoplantaris. They also include chronic recurrent multifocal osteomyelitis (CRMO), another entity that is more common in children and not primarily characterised by dermatologic symptoms [13], [14], [15]. Mainly the association of palmoplantar pustulosis with osteoarticular manifestations such as involvement of the spine led to the subsumption of the SAPHO syndrome among the group of the SpAs [16], [17]. Although there seems to be only a weak association with the HLA-B27 allele, this concept is further supported by the periodic occurrence of sacroiliitis and synovitis of large joints of the lower extremity in these patients [18].
Modern diagnostic modalities like whole-body MRI for the early detection of subtle bony lesions and ultrasonography for the sensitive detection of synovitis add substantially to conventional tools like computed tomography and bone scintigraphy, which can visualise hyperostosis and the typical bull's head sign of the anterior chest wall, respectively [19], [20], [21] (Fig. 1). Also, new therapeutic options have evolved and a broad variety of medications have been tried for the treatment of the disease. Among them were NSAIDs, corticosteroids and various disease-modifying anti-rheumatic drugs (DMARDs) with varying therapeutic effects [18], [22], [23]. Antibiotics have been used under the perception of an underlying infectious agent and have shown some efficacy [24]. CRMO and the skeletal manifestations of SAPHO seem to respond quite well to bisphosphonates [25], [26], [27], [28], [29], [30]. Other promising reports and case series have been published in recent years with the use of TNF-blocking agents and, in a few cases, with IL1 inhibition [31], [32], [33], [34], [35], [36].
This work was intended to get a current overview of disease manifestations, course of diagnosis, treatment regimen and disease burden of the SAPHO syndrome in a nationwide cohort.
Section snippets
Methods
Patients were recruited from a university rheumatology centre in southern Germany and via a nationwide support group for SAPHO patients. After written informed consent was obtained, the patients were asked to complete a comprehensive questionnaire and to provide their medical records concerning the diagnosis of SAPHO.
The questionnaires to be filled out by the patients covered 4 aspects of the disease: (1) course of diagnosis, (2) current disease burden, (3) current and past disease
Characteristics of the study population
Overall, 121 patients were contacted, of which 77 agreed on study participation. After review of the medical records, 13 patients were excluded because they did not fulfil the current classification criteria of the SAPHO syndrome, resulting in a total number of 64 patients with the SAPHO syndrome. Of those, 21 patients were recruited directly in the rheumatology outpatient department of the University Hospital of Munich, while 43 patients were recruited via the internet platform of the
Discussion
Given the rarity of the syndrome, this cohort of 64 SAPHO patients represents one of the largest cohorts described so far. In addition to the characterisation of clinical features, data on MRI and biologics are considered as well, thereby also including important diagnostic and therapeutic advances of the last years. Further, the distinct strength of our study is the focus on the patients' perspective by means of multiple patient-related outcome measurements such as the HAQ, the SF-36
Conclusion
Taken together, the diagnostic and therapeutic advances which improved the care of SpA patients have not reached the SAPHO population. The SAPHO syndrome seems to be underdiagnosed and has a high impact on the affected patients' general health and quality of life. Establishing the diagnosis still takes years and expends multiple medical resources. Even in the era of biologics, obviously a potentially very effective treatment, these are rarely prescribed, and current disease burden and
Acknowledgements
We thank all the patients for taking part in this survey, in particular the members of the “SAPHO Selbsthilfe” patient support group.
References (40)
- et al.
The SAPHO syndrome
Baillieres Clin Rheumatol
(1994) - et al.
Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris
J Pediatr
(1978) - et al.
SAPHO syndrome: a long-term follow-up study of 120 cases
Semin Arthritis Rheum
(1999) - et al.
The SAPHO syndrome
Semin Arthritis Rheum
(2012) - et al.
A case of SAPHO syndrome with diffuse sclerosing osteomyelitis of the mandible treated successfully with prednisolone and bisphosphonate
J Oral Maxillofac Surg
(2012) - et al.
The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Ann Rheum Dis
(2009) - et al.
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48
Ann Rheum Dis
(2011) - et al.
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis
Ann Rheum Dis
(2012) - et al.
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Ann Rheum Dis
(2013) - et al.
European League against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
Ann Rheum Dis
(2012)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Ann Rheum Dis
Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases
Rev Rhum Mal Osteoartic
Pustulosis palmaris et plantaris: its association with chronic recurrent multifocal osteomyelitis
J Am Acad Dermatol
Sternocostoclavicular hyperostosis. A report of nineteen cases, with special reference to etiology and treatment
J Bone Joint Surg Am
Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis
Ann Rheum Dis
Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies?
Clin Exp Rheumatol
Subacute and chronic “symmetrical” osteomyelitis
Ann Radiol (Paris)
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process
Pediatr Infect Dis J
Clinical features of 53 cases with pustulotic arthro-osteitis
Ann Rheum Dis
SAPHO syndrome associated spondylitis
Eur Spine J
Cited by (43)
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome presenting with a cervical vertebral fracture: A case report
2021, North American Spine Society JournalCitation Excerpt :Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition considered as a type of seronegative spondyloarthritis [1–3]. The prevalence of SAPHO syndrome has been estimated as 1 in 10,000 previously, however, SAPHO syndrome is likely underdiagnosed [4–7]. There are no validated diagnostic criteria for SAPHO syndrome and no guidelines for treatment.
Spinal and sacroiliac involvement in SAPHO syndrome: A single center study of a cohort of 354 patients
2019, Seminars in Arthritis and RheumatismComparison of<sup>68</sup>Ga-DOTA-FAPI-04 and<sup>18</sup>F-FDG PET/CT in Patients With SAPHO Syndrome
2023, Clinical Nuclear MedicineClinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a meta-analysis
2023, Rheumatology (United Kingdom)